---
title: "How long does iron take to correct deficiency, and when to retest?"
url: https://nutritailor.co.uk/apps/learn/how-long-does-iron-supplementation-take-to-correct-deficiency-and-when-should-it
slug: how-long-does-iron-supplementation-take-to-correct-deficiency-and-when-should-it
pillar: Iron
last_reviewed: 13 May 2026
confidence: strong
publisher: "Nutri Tailor Health Reference Library"
editor: "Henry Bond"
---

# How long does iron take to correct deficiency, and when to retest?

## Summary

Iron repletion runs in two phases at different speeds. Haemoglobin recovers in weeks; ferritin in months. Per BSG 2021: oral iron raises haemoglobin within 1-2 weeks and normalises Hb within 6-8 weeks. Continue 3 months past Hb normalisation to replenish stores. Endpoint is clinical (symptom resolution, restored stores), not a numerical ferritin target. Standard retest schedule: FBC at 2-4 weeks, FBC plus ferritin at 8-12 weeks, final ferritin at 6 months.

## How it works

Moretti 2015 (Blood 126(17):1981-1989, PMID 26289639) demonstrated that consecutive-day dosing of 60 mg elemental iron triggered hepcidin elevations reducing absorption from the next dose by 35-45%. Stoffel 2017 (Lancet Haematol 4(11):e524-e533, PMID 29032957), Stoffel 2020 (Haematologica 105(5):1232-1239) confirmed the practical implication: alternate-day dosing achieves higher cumulative fractional absorption and comparable haemoglobin response with fewer GI side effects than consecutive-day dosing.

## Effective dose

Form choice does not materially change the repletion timeline. BSG 2021 considers ferrous sulphate, fumarate, and gluconate equivalent first-line options for repletion. Iron bisglycinate has tolerability advantages but no proven superiority on absorption rate or repletion speed. Switching between traditional iron salts is not evidence-supported.

## Timing

Ferritin trails haemoglobin substantially. After Hb normalises, ferritin continues to rise over a further 3-6 months on continued repletion. BSG 2021 recommends continuing oral iron for 3 months past Hb normalisation rather than stopping at the first normal Hb. Standard retest schedule: FBC at 2-4 weeks; FBC plus ferritin at 8-12 weeks; final ferritin at around 6 months. For IDWA: no Hb endpoint, so retest ferritin and FBC at 8-12 weeks.

## Safety profile

Documented causes of slower-than-expected response: ongoing blood loss (heavy menstrual or occult gastrointestinal); malabsorption (coeliac disease, IBD, atrophic gastritis, H. pylori, post-bariatric); inflammation suppressing absorption and elevating ferritin (Ganz 2019 NEJM 381(12):1148-1157, PMID 31532961); consecutive-day dosing hitting hepcidin rebound (Moretti 2015); co-administration with calcium, polyphenols, or antacids; thyroid medication interaction requiring spacing; inadequate dose or non-adherence driven by GI side effects (Tolkien 2015 PLoS One 10(2):e0117383, PMID 25700159).

## Special populations

In IDWA, retest ferritin and FBC at 8-12 weeks; if response is inadequate, reassess underlying cause rather than escalating dose blindly. Repletion duration in IDWA is more individualised than in IDA because no Hb endpoint forces the question; typically 3-6 months with ferritin retest before stopping. Pregnancy: iron requirements rise substantially; routine antenatal screening covers iron, B12, and folate. Inflammatory contexts: paired ferritin and CRP avoids misreading falsely elevated ferritin as repletion.

## Interactions

Concurrent intake of these inhibitors with iron can blunt absorption and slow repletion. Practical mitigation: take iron away from these (1-2 hours before or after coffee, tea, or calcium-containing foods; at least 4 hours from levothyroxine). Stoffel/Moretti programme findings on alternate-day dosing apply regardless of these timing arrangements.

## Guideline positions

Moretti 2015 (Blood 126(17):1981-1989, PMID 26289639), Stoffel 2017 (Lancet Haematol 4(11):e524-e533, PMID 29032957), Stoffel 2020 (Haematologica 105(5):1232-1239) underpin the alternate-day dosing approach. Tolkien 2015 (PLoS One 10(2):e0117383, PMID 25700159) quantifies GI tolerability of ferrous sulphate. Ganz 2019 (NEJM 381(12):1148-1157, PMID 31532961) covers anaemia of inflammation.

## Practical framework

After 8-12 weeks of adequate adherence without expected response, BSG 2021 supports investigating underlying cause before concluding non-response: occult GI bleeding workup, coeliac serology, H. pylori testing, inflammatory markers, and review of co-administration patterns. Where investigation is complete and oral iron has genuinely failed or is not tolerated, parenteral iron (e.g. ferric carboxymaltose) is the BSG-supported next-line option. Krayenbuehl 2011 (Blood 118(12):3222-3227, PMID 21705493) anchors the IV iron measurement window at 6 weeks post-infusion. This is a summary of published research, not personal health advice. Discuss any health or supplement decisions with a qualified healthcare professional, particularly during ongoing care, pregnancy, or with chronic conditions.

## Common misconceptions

**Claim: doubling the dose halves the timeline.** The Tolkien 2015 meta-regression found no significant relationship between iron dose and GI side-effect rate. Higher single doses do not proportionally increase absorption because hepcidin elevation after each dose dampens subsequent uptake. The Moretti 2015 / Stoffel 2017 / Stoffel 2020 findings on alternate-day dosing are the practical answer to absorption efficiency, not dose escalation. Form switching between traditional iron salts is not evidence-supported.

## Who this matters for

- Pregnancy
- Breastfeeding
- Adults over 65
- Post-menopause
- Inflammatory bowel disease
- People taking levothyroxine
- People taking proton pump inhibitors
- Vegetarian diet

## Sources

1. Snook J, Bhala N, Beales ILP, Cannings D, Kightley C, Logan RPH, Pritchard DM, Sidhu R, Surgenor S, Thomas W, Verma AM (2021). British Society of Gastroenterology guidelines for the management of iron deficiency anaemia in adults. Gut. PMID: 34497146. DOI: 10.1136/gutjnl-2021-325210.
2. Camaschella C (2015). Iron-deficiency anemia. New England Journal of Medicine. PMID: 25946282. DOI: 10.1056/nejmra1401038.
3. Camaschella C (2019). Iron deficiency. Blood. PMID: 30401704. DOI: 10.1182/blood-2018-05-815944.
4. Moretti D, Goede JS, Zeder C, Jiskra M, Chatzinakou V, Tjalsma H, Melse-Boonstra A, Brittenham G, Swinkels DW, Zimmermann MB (2015). Oral iron supplements increase hepcidin and decrease iron absorption from daily or twice-daily doses in iron-depleted young women. Blood. PMID: 26289639. DOI: 10.1182/blood-2015-05-642223.
5. Stoffel NU, Cercamondi CI, Brittenham G, Zeder C, Geurts-Moespot AJ, Swinkels DW, Moretti D, Zimmermann MB (2017). Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twice-daily split dosing in iron-depleted women: two open-label, randomised controlled trials. Lancet Haematology. PMID: 29032957. DOI: 10.1016/s2352-3026(17)30182-5.
6. Stoffel NU, Zeder C, Brittenham GM, Moretti D, Zimmermann MB (2020). Iron absorption from supplements is greater with alternate day than with consecutive day dosing in iron-deficient anemic women. Haematologica. PMID: 31413088. DOI: 10.3324/haematol.2019.220830.
7. Tolkien Z, Stecher L, Mander AP, Pereira DI, Powell JJ (2015). Ferrous sulfate supplementation causes significant gastrointestinal side-effects in adults: a systematic review and meta-analysis. PLoS One. PMID: 25700159. DOI: 10.1371/journal.pone.0117383.
8. Verdon F, Burnand B, Stubi CL, Bonard C, Graff M, Michaud A, Bischoff T, de Vevey M, Studer JP, Herzig L, Chapuis C, Tissot J, Pécoud A, Favrat B (2003). Iron supplementation for unexplained fatigue in non-anaemic women: double blind randomised placebo controlled trial. BMJ. PMID: 12763985. DOI: 10.1136/bmj.326.7399.1124.
9. Vaucher P, Druais P-L, Waldvogel S, Favrat B (2012). Effect of iron supplementation on fatigue in nonanemic menstruating women with low ferritin: a randomized controlled trial. CMAJ. PMID: 22777991. DOI: 10.1503/cmaj.110950.
10. Krayenbuehl PA, Battegay E, Breymann C, Furrer J, Schulthess G (2011). Intravenous iron for the treatment of fatigue in nonanemic, premenopausal women with low serum ferritin concentration. Blood. PMID: 21705493. DOI: 10.1182/blood-2011-04-346304.
11. Ganz T (2019). Anemia of inflammation. New England Journal of Medicine. PMID: 31532961. DOI: 10.1056/nejmra1804281.